X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA SUVEN LIFE ELDER PHARMA/
SUVEN LIFE
 
P/E (TTM) x -0.2 17.0 - View Chart
P/BV x 0.1 3.5 2.9% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
SUVEN LIFE
Mar-18
ELDER PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs380251 151.5%   
Low Rs188155 121.3%   
Sales per share (Unadj.) Rs491.249.1 999.9%  
Earnings per share (Unadj.) Rs-3.29.7 -32.7%  
Cash flow per share (Unadj.) Rs14.411.4 126.5%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs376.560.3 624.5%  
Shares outstanding (eoy) m20.54127.28 16.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.1 14.0%   
Avg P/E ratio x-89.320.9 -427.5%  
P/CF ratio (eoy) x19.717.8 110.7%  
Price / Book Value ratio x0.83.4 22.4%  
Dividend payout %015.4 0.0%   
Avg Mkt Cap Rs m5,83325,825 22.6%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m2,179613 355.6%   
Avg. sales/employee Rs ThNM5,832.6-  
Avg. wages/employee Rs ThNM571.5-  
Avg. net profit/employee Rs ThNM1,153.8-  
INCOME DATA
Net Sales Rs m10,0896,253 161.4%  
Other income Rs m257233 110.3%   
Total revenues Rs m10,3466,485 159.5%   
Gross profit Rs m-7921,982 -40.0%  
Depreciation Rs m361213 169.5%   
Interest Rs m2,75646 5,953.1%   
Profit before tax Rs m-3,6531,955 -186.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125718 17.4%   
Profit after tax Rs m-651,237 -5.3%  
Gross profit margin %-7.831.7 -24.8%  
Effective tax rate %-3.436.7 -9.3%   
Net profit margin %-0.619.8 -3.3%  
BALANCE SHEET DATA
Current assets Rs m9,2405,622 164.3%   
Current liabilities Rs m9,9981,168 856.3%   
Net working cap to sales %-7.571.2 -10.5%  
Current ratio x0.94.8 19.2%  
Inventory Days Days4681 56.9%  
Debtors Days Days6036 166.8%  
Net fixed assets Rs m10,1243,325 304.5%   
Share capital Rs m206127 161.6%   
"Free" reserves Rs m5,5827,547 74.0%   
Net worth Rs m7,7347,674 100.8%   
Long term debt Rs m4,88914 35,172.7%   
Total assets Rs m22,8829,135 250.5%  
Interest coverage x-0.343.2 -0.8%   
Debt to equity ratio x0.60 34,902.5%  
Sales to assets ratio x0.40.7 64.4%   
Return on assets %11.814.0 83.7%  
Return on equity %-0.816.1 -5.2%  
Return on capital %22.326.0 85.7%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3075,066 6.1%   
Fx outflow Rs m1252,001 6.3%   
Net fx Rs m1813,065 5.9%   
CASH FLOW
From Operations Rs m11,754699 1,680.6%  
From Investments Rs m-561-6 9,188.5%  
From Financial Activity Rs m-6,762-577 1,171.9%  
Net Cashflow Rs m4,432116 3,810.6%  

Share Holding

Indian Promoters % 39.6 63.4 62.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 0.0 -  
FIIs % 16.8 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 36.5 98.9%  
Shareholders   16,479 37,287 44.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   DR. REDDYS LAB  IPCA LABS  ASTRAZENECA PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets End Lower; Metal Stocks Top Losers(Closing)

Indian share markets settled lower today led by a fall in the financial stocks after the rupee hit a record low of 70.32 per dollar.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

SUVEN LIFE Announces Quarterly Results (4QFY18); Net Profit Up 56.0% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SUVEN LIFE has posted a net profit of Rs 625 m (up 56.0% YoY). Sales on the other hand came in at Rs 2 bn (up 18.6% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS